Published by
@ShahidNShah
@ShahidNShah
Cue Health to develop omicron-specific test through HHS partnership
HHS' Biomedical Advanced Research and Development Authority will provide additional funds to its ongoing partnership with San Diego-based Cue Health, a healthcare technology company, to develop an omicron-genotyping COVID-19 test.
The test will complement the already existing Cue molecular COVID-19 test and will be compatible with the Cue Health Monitoring System and the Cue Health Mobile Application, according to a Jan. 6 press release.
"An omicron-specific test will assist clinicians in providing patients better treatment options and containment strategies at the time of a positive diagnosis," Cue CEO Ayub Khattak said in the press release.
Since 2018, HHS' BARDA has funded Cue Health projects like over-the-counter influenza diagnostic cartridges for its monitoring system and its portable COVID-19 test.
Continue reading at beckershospitalreview.com
Make faster decisions with community advice
- Mortality rates dropped 33% at NYC hospital after NYU Langone merger, study finds
- ONC releases data standard for patient addresses: 4 things to know
- IT execs talk priorities and predictions for 2022
- Pharmacists' active involvement needed to bolster telepharmacy in Japan's rural communities
- 2022 predictions: Health tech suppliers have their say
Next Article
-
Mortality rates dropped 33% at NYC hospital after NYU Langone merger, study finds
In-hospital mortality rates decreased by 33 percent at New York City-based NYU Langone Hospital-Brooklyn — previously named Lutheran Medical Center — after it merged with NYU Langone Health, a Jan. 6 …
Posted Jan 10, 2022 Hospital Mergers & Acquisitions
